

Michele Maio

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2549462/publications.pdf>

Version: 2024-02-01

232
papers

63,439
citations

7087

78
h-index

1113

231
g-index

254
all docs

254
docs citations

254
times ranked

48072
citing authors

#	ARTICLE	IF	CITATIONS
1	Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation. <i>New England Journal of Medicine</i> , 2011, 364, 2507-2516.	13.9	6,976
2	Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. <i>New England Journal of Medicine</i> , 2015, 373, 23-34.	13.9	6,773
3	Nivolumab in Previously Untreated Melanoma without BRAF Mutation. <i>New England Journal of Medicine</i> , 2015, 372, 320-330.	13.9	4,795
4	Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma. <i>New England Journal of Medicine</i> , 2011, 364, 2517-2526.	13.9	4,074
5	Overall Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1345-1356.	13.9	3,589
6	Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria. <i>Clinical Cancer Research</i> , 2009, 15, 7412-7420.	3.2	2,857
7	Five-Year Survival with Combined Nivolumab and Ipilimumab in Advanced Melanoma. <i>New England Journal of Medicine</i> , 2019, 381, 1535-1546.	13.9	2,484
8	Nivolumab versus chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. <i>Lancet Oncology</i> , The, 2015, 16, 375-384.	5.1	2,353
9	Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma. <i>New England Journal of Medicine</i> , 2014, 371, 1867-1876.	13.9	1,824
10	Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma. <i>New England Journal of Medicine</i> , 2017, 377, 1824-1835.	13.9	1,752
11	International validation of the consensus Immunoscore for the classification of colon cancer: a prognostic and accuracy study. <i>Lancet</i> , The, 2018, 391, 2128-2139.	6.3	1,487
12	Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma. <i>New England Journal of Medicine</i> , 2018, 378, 1789-1801.	13.9	1,441
13	Ipilimumab versus placebo after radiotherapy in patients with metastatic castration-resistant prostate cancer that had progressed after docetaxel chemotherapy (CA184-043): a multicentre, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2014, 15, 700-712.	5.1	1,280
14	Towards the introduction of the Immunoscore™ in the classification of malignant tumours. <i>Journal of Pathology</i> , 2014, 232, 199-209.	2.1	1,151
15	Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy. <i>New England Journal of Medicine</i> , 2016, 375, 1845-1855.	13.9	1,140
16	Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC Tj ETQq0 0 0 rgBT /Overlock 10 Tf	5.1	1,093
17	Safety and efficacy of vemurafenib in BRAFV600E and BRAFV600K mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. <i>Lancet Oncology</i> , The, 2014, 15, 323-332.	5.1	890
18	High Levels of Exosomes Expressing CD63 and Caveolin-1 in Plasma of Melanoma Patients. <i>PLoS ONE</i> , 2009, 4, e5219.	1.1	806

#	ARTICLE	IF	CITATIONS
19	Phase III Randomized Clinical Trial Comparing Tremelimumab With Standard-of-Care Chemotherapy in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 616-622.	0.8	720
20	Cancer classification using the Immunoscore: a worldwide task force. <i>Journal of Translational Medicine</i> , 2012, 10, 205.	1.8	676
21	The role of BRAF V600 mutation in melanoma. <i>Journal of Translational Medicine</i> , 2012, 10, 85.	1.8	563
22	Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab. <i>Clinical Cancer Research</i> , 2016, 22, 5487-5496.	3.2	480
23	Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab. <i>Clinical Cancer Research</i> , 2016, 22, 2908-2918.	3.2	459
24	Long-Term Outcomes With Nivolumab Plus Ipilimumab or Nivolumab Alone Versus Ipilimumab in Patients With Advanced Melanoma. <i>Journal of Clinical Oncology</i> , 2022, 40, 127-137.	0.8	446
25	Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial. <i>Journal of Clinical Oncology</i> , 2015, 33, 1191-1196.	0.8	445
26	Ipilimumab 10 mg/kg versus ipilimumab 3 mg/kg in patients with unresectable or metastatic melanoma: a randomised, double-blind, multicentre, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 611-622.	5.1	428
27	Vaccination of Metastatic Melanoma Patients With Autologous Tumor-Derived Heat Shock Protein gp96-Peptide Complexes: Clinical and Immunologic Findings. <i>Journal of Clinical Oncology</i> , 2002, 20, 4169-4180.	0.8	361
28	Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial. <i>Lancet Oncology</i> , The, 2017, 18, 1261-1273.	5.1	356
29	Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2020, 21, 1465-1477.	5.1	330
30	Tremelimumab for patients with chemotherapy-resistant advanced malignant mesothelioma: an open-label, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2013, 14, 1104-1111.	5.1	326
31	Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody. <i>Clinical Cancer Research</i> , 2017, 23, 1929-1936.	3.2	290
32	The biology of cancer testis antigens: Putative function, regulation and therapeutic potential. <i>Molecular Oncology</i> , 2011, 5, 164-182.	2.1	281
33	Ipilimumab and fotemustine in patients with advanced melanoma (NIBIT-M1): an open-label, single-arm phase 2 trial. <i>Lancet Oncology</i> , The, 2012, 13, 879-886.	5.1	273
34	Therapeutic efficacy of ipilimumab, an anti-CTLA-4 monoclonal antibody, in patients with metastatic melanoma unresponsive to prior systemic treatments: clinical and immunological evidence from three patient cases. <i>Cancer Immunology, Immunotherapy</i> , 2009, 58, 1297-1306.	2.0	246
35	The Emerging Toxicity Profiles of Anti-CTLA-4 Antibodies Across Clinical Indications. <i>Seminars in Oncology</i> , 2010, 37, 499-507.	0.8	224
36	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial. <i>Lancet Oncology</i> , The, 2021, 22, 643-654.	5.1	224

#	ARTICLE	IF	CITATIONS
37	Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenetic blood vessels. <i>Oncogene</i> , 2003, 22, 6557-6563.	2.6	222
38	Myeloid-Derived Suppressor Cells Predict Survival of Patients with Advanced Melanoma: Comparison with Regulatory T Cells and NY-ESO-1- or Melan-Aâ€“Specific T Cells. <i>Clinical Cancer Research</i> , 2014, 20, 1601-1609.	3.2	222
39	Intratumor Heterogeneity of Cancer/Testis Antigens Expression in Human Cutaneous Melanoma Is Methylation-Regulated and Functionally Reverted by 5-Aza-2â€“deoxycytidine. <i>Cancer Research</i> , 2004, 64, 9167-9171.	0.4	193
40	Pembrolizumab in Patients With Microsatellite Instabilityâ€“High Advanced Endometrial Cancer: Results From the KEYNOTE-158 Study. <i>Journal of Clinical Oncology</i> , 2022, 40, 752-761.	0.8	189
41	Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2013, 31, 2413-2420.	0.8	188
42	Efficacy and safety of an intensified schedule of tremelimumab for chemotherapy-resistant malignant mesothelioma: an open-label, single-arm, phase 2 study. <i>Lancet Respiratory Medicine</i> , 2015, 3, 301-309.	5.2	185
43	Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study. <i>Lancet Respiratory Medicine</i> , 2018, 6, 451-460.	5.2	185
44	Adjuvant vemurafenib in resected, BRAFV600 mutation-positive melanoma (BRIM8): a randomised, double-blind, placebo-controlled, multicentre, phase 3 trial. <i>Lancet Oncology</i> , 2018, 19, 510-520.	5.1	183
45	Durable benefit and the potential for long-term survival with immunotherapy in advanced melanoma. <i>Cancer Treatment Reviews</i> , 2014, 40, 1056-1064.	3.4	178
46	Endoglin: An accessory component of the TGF-?binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. <i>Journal of Cellular Physiology</i> , 2001, 188, 1-7.	2.0	162
47	Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma and peritoneal fluid from ovarian cancer patients. <i>Women's Oncology Review</i> , 2005, 5, 19-21.	0.0	159
48	Clinical experience with ipilimumab 3Âˆmg/kg: real-world efficacy and safety data from an expanded access programme cohort. <i>Journal of Translational Medicine</i> , 2014, 12, 116.	1.8	149
49	Efficacy and safety of ipilimumab 3mg/kg in patients with pretreated, metastatic, mucosal melanoma. <i>European Journal of Cancer</i> , 2014, 50, 121-127.	1.3	149
50	Targeting cancer vasculature via endoglin/CD105: a novel antibody-based diagnostic and therapeutic strategy in solid tumours. <i>Cardiovascular Research</i> , 2010, 86, 12-19.	1.8	147
51	Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25. <i>Cell Research</i> , 2015, 25, 208-224.	5.7	143
52	Highlights on endoglin (CD105): from basic findings towards clinical applications in human cancer. <i>Journal of Translational Medicine</i> , 2004, 2, 18.	1.8	139
53	Defining the critical hurdles in cancer immunotherapy. <i>Journal of Translational Medicine</i> , 2011, 9, 214.	1.8	139
54	Intralesional administration of L19-IL2/L19-TNF in stage III or stage IVM1a melanoma patients: results of a phase II study. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 999-1009.	2.0	138

#	ARTICLE	IF	CITATIONS
55	A phase II trial of vaccination with autologous, tumor-derived heat-shock protein peptide complexes Gp96, in combination with GM-CSF and interferon- γ in metastatic melanoma patients. <i>Cancer Immunology, Immunotherapy</i> , 2006, 55, 958-968.	2.0	134
56	Adjuvant ipilimumab versus placebo after complete resection of stage III melanoma: long-term follow-up results of the European Organisation for Research and Treatment of Cancer 18071 double-blind phase 3 randomised trial. <i>European Journal of Cancer</i> , 2019, 119, 1-10.	1.3	132
57	Multicenter International Society for Immunotherapy of Cancer Study of the Consensus Immunoscore for the Prediction of Survival and Response to Chemotherapy in Stage III Colon Cancer. <i>Journal of Clinical Oncology</i> , 2020, 38, 3638-3651.	0.8	130
58	Epigenetic drugs as pleiotropic agents in cancer treatment: Biomolecular aspects and clinical applications. <i>Journal of Cellular Physiology</i> , 2007, 212, 330-344.	2.0	124
59	Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 1021-1028.	2.0	121
60	Functional Up-regulation of Human Leukocyte Antigen Class I Antigens Expression by 5-aza-2'-deoxycytidine in Cutaneous Melanoma: Immunotherapeutic Implications. <i>Clinical Cancer Research</i> , 2007, 13, 3333-3338.	3.2	120
61	Prolonged Upregulation of the Expression of HLA Class I Antigens and Co stimulatory Molecules on Melanoma Cells Treated with 5-aza-2'-deoxycytidine (5-AZA-CdR). <i>Journal of Immunotherapy</i> , 1999, 22, 16-24.	1.2	119
62	Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy. <i>Cancer Immunology, Immunotherapy</i> , 2012, 61, 41-48.	2.0	118
63	Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study. <i>Annals of Oncology</i> , 2015, 26, 798-803.	0.6	118
64	Heat shock proteins: biological functions and clinical application as personalized vaccines for human cancer. <i>Cancer Immunology, Immunotherapy</i> , 2004, 53, 227-233.	2.0	116
65	5-aza-2'-deoxycytidine-induced expression of functional cancer testis antigens in human renal cell carcinoma: immunotherapeutic implications. <i>Clinical Cancer Research</i> , 2002, 8, 2690-5.	3.2	114
66	Functional T Cells Targeting NY-ESO-1 or Melan-A Are Predictive for Survival of Patients With Distant Melanoma Metastasis. <i>Journal of Clinical Oncology</i> , 2012, 30, 1835-1841.	0.8	112
67	Promoter Methylation Controls the Expression of MAGE2, 3 and 4 Genes in Human Cutaneous Melanoma. <i>Journal of Immunotherapy</i> , 2002, 25, 16-26.	1.2	111
68	Recommendations from the iSBTc-SITC/FDA/NCI Workshop on Immunotherapy Biomarkers. <i>Clinical Cancer Research</i> , 2011, 17, 3064-3076.	3.2	108
69	Efficacy and safety of ipilimumab in patients with advanced melanoma and brain metastases. <i>Journal of Neuro-Oncology</i> , 2014, 118, 109-116.	1.4	103
70	Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2014, 33, 30.	3.5	97
71	Epigenetics of human cutaneous melanoma: setting the stage for new therapeutic strategies. <i>Journal of Translational Medicine</i> , 2010, 8, 56.	1.8	94
72	Epigenetic drugs as immunomodulators for combination therapies in solid tumors. , 2014, 142, 339-350.		92

#	ARTICLE	IF	CITATIONS
73	Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial. <i>Lancet Oncology</i> , The, 2017, 18, 393-403.	5.1	91
74	Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program. <i>Cancer Investigation</i> , 2014, 32, 144-149.	0.6	90
75	Molecular Pathways: At the Crossroads of Cancer Epigenetics and Immunotherapy. <i>Clinical Cancer Research</i> , 2015, 21, 4040-4047.	3.2	89
76	Peripheral CD8 effector-memory type 1 T-cells correlate with outcome in ipilimumab-treated stage IV melanoma patients. <i>European Journal of Cancer</i> , 2017, 73, 61-70.	1.3	88
77	Challenges in lung cancer therapy during the COVID-19 pandemic. <i>Lancet Respiratory Medicine</i> , the, 2020, 8, 542-544.	5.2	88
78	Updated overall survival (OS) results for BRIM-3, a phase III randomized, open-label, multicenter trial comparing BRAF inhibitor vemurafenib (vem) with dacarbazine (DTIC) in previously untreated patients with <i>BRAF</i> ^{V600E} -mutated melanoma.. <i>Journal of Clinical Oncology</i> , 2012, 30, 8502-8502.	0.8	86
79	Limited Antitumor T Cell Response in Melanoma Patients Vaccinated with Interleukin-2 Gene-Transduced Allogeneic Melanoma Cells. <i>Human Gene Therapy</i> , 1996, 7, 1955-1963.	1.4	83
80	Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy). <i>Cancer Immunology, Immunotherapy</i> , 2011, 60, 467-477.	2.0	79
81	5-Aza-2â€²-deoxycytidine (decitabine) treatment of hematopoietic malignancies: a multimechanism therapeutic approach?. <i>Blood</i> , 2003, 101, 4644-4646.	0.6	78
82	Chemokine receptor patterns in lymphocytes mirror metastatic spreading in melanoma. <i>Journal of Clinical Investigation</i> , 2016, 126, 921-937.	3.9	71
83	Immunotherapy of brain metastases: breaking a â€œdogmaâ€. <i>Journal of Experimental and Clinical Cancer Research</i> , 2019, 38, 419.	3.5	70
84	Epigenetic targets for immune intervention in human malignancies. <i>Oncogene</i> , 2003, 22, 6484-6488.	2.6	68
85	Immune Checkpoint Inhibitors in Melanoma Provide the Cornerstones for Curative Therapies. <i>Seminars in Oncology</i> , 2015, 42, 429-435.	0.8	68
86	Active immunization of metastatic melanoma patients with interleukin-2-transduced allogeneic melanoma cells: evaluation of efficacy and tolerability. <i>Cancer Immunology, Immunotherapy</i> , 1997, 44, 197-203.	2.0	67
87	CXCR6, a Newly Defined Biomarker of Tissue-Specific Stem Cell Asymmetric Self-Renewal, Identifies More Aggressive Human Melanoma Cancer Stem Cells. <i>PLoS ONE</i> , 2010, 5, e15183.	1.1	65
88	Implementing liquid biopsies into clinical decision making for cancer immunotherapy. <i>Oncotarget</i> , 2017, 8, 48507-48520.	0.8	63
89	Heat Shock Proteins and Their Use as Anticancer Vaccines. <i>Clinical Cancer Research</i> , 2004, 10, 8142-8146.	3.2	62
90	Large Randomized Study of Thymosin Î± 1, Interferon Alfa, or Both in Combination With Dacarbazine in Patients With Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2010, 28, 1780-1787.	0.8	62

#	ARTICLE	IF	CITATIONS
91	Vaccination of Melanoma Patients with Interleukin 4 Gene-Transduced Allogeneic Melanoma Cells. <i>Human Gene Therapy</i> , 1999, 10, 2907-2916.	1.4	61
92	Analysis of Cancer/Testis Antigens in Sporadic Medullary Thyroid Carcinoma: Expression and Humoral Response to NY-ESO-1. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 748-754.	1.8	61
93	Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class II-Modified Peptides. <i>Clinical Cancer Research</i> , 2012, 18, 6485-6496.	3.2	61
94	Immunomodulatory activity of SGI-110, a 5-aza-2'-deoxycytidine-containing demethylating dinucleotide. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 605-614.	2.0	61
95	Antitumor activity of epigenetic immunomodulation combined with CTLA-4 blockade in syngeneic mouse models. <i>Oncolmmunology</i> , 2015, 4, e1019978.	2.1	61
96	Safety and efficacy of nivolumab in patients with rare melanoma subtypes who progressed on or after ipilimumab treatment: a single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 119, 168-178.	1.3	61
97	Guadecitabine Plus Ipilimumab in Unresectable Melanoma: The NIBIT-M4 Clinical Trial. <i>Clinical Cancer Research</i> , 2019, 25, 7351-7362.	3.2	61
98	MODULATION OF HLA-DR ANTIGENS EXPRESSION IN HUMAN MYELOID LEUKAEMIA CELLS BY CYTARABINE AND 5-AZA-2'-DEOXYCYTIDINE. <i>Lancet, The</i> , 1984, 324, 867-868.	6.3	59
99	Peptide-based vaccines for cancer therapy. <i>Human Vaccines and Immunotherapeutics</i> , 2014, 10, 3175-3178.	1.4	59
100	Cancer testis antigens in human melanoma stem cells: Expression, distribution, and methylation status. <i>Journal of Cellular Physiology</i> , 2008, 215, 287-291.	2.0	56
101	Bempegaldesleukin Plus Nivolumab in First-Line Metastatic Melanoma. <i>Journal of Clinical Oncology</i> , 2021, 39, 2914-2925.	0.8	55
102	Phenotypic and functional changes of human melanoma xenografts induced by DNA hypomethylation: Immunotherapeutic implications. <i>Journal of Cellular Physiology</i> , 2006, 207, 58-66.	2.0	52
103	Clinical Studies With Anti-CTLA-4 Antibodies in Non-melanoma Indications. <i>Seminars in Oncology</i> , 2010, 37, 460-467.	0.8	52
104	Methylation levels of the "long interspersed nucleotide element-1" repetitive sequences predict survival of melanoma patients. <i>Journal of Translational Medicine</i> , 2011, 9, 78.	1.8	52
105	Whole genome methylation profiles as independent markers of survival in stage IIIC melanoma patients. <i>Journal of Translational Medicine</i> , 2012, 10, 185.	1.8	49
106	Differential levels of soluble endoglin (CD105) in myeloid malignancies. <i>Journal of Cellular Physiology</i> , 2003, 194, 171-175.	2.0	48
107	Targeted therapy of solid malignancies via HLA class II antigens: a new biotherapeutic approach?. <i>Oncogene</i> , 2003, 22, 6564-6569.	2.6	46
108	Strong association between an HLA-DR antigen and thyroid carcinoma. <i>Tissue Antigens</i> , 1982, 20, 155-158.	1.0	45

#	ARTICLE	IF	CITATIONS
109	A systematic approach to biomarker discovery; Preamble to "the iSBTc-FDA taskforce on immunotherapy biomarkers". Journal of Translational Medicine, 2008, 6, 81.	1.8	45
110	Epigenetic Modulation of Solid Tumors as a Novel Approach for Cancer Immunotherapy. Seminars in Oncology, 2005, 32, 473-478.	0.8	44
111	Conservation of Genetic Alterations in Recurrent Melanoma Supports the Melanoma Stem Cell Hypothesis. Cancer Research, 2008, 68, 122-131.	0.4	42
112	Soluble NKG2D ligands are biomarkers associated with the clinical outcome to immune checkpoint blockade therapy of metastatic melanoma patients. OncoImmunology, 2017, 6, e1323618.	2.1	42
113	Methylation-regulated expression of HLA class I antigens in melanoma. International Journal of Cancer, 2003, 105, 430-431.	2.3	41
114	Biology and Clinical Applications of CD40 in Cancer Treatment. Seminars in Oncology, 2010, 37, 517-523.	0.8	41
115	The Coincidence of Chromosome 15 Aberrations and β 2-Microglobulin Gene Mutations Is Causative for the Total Loss of Human Leukocyte Antigen Class I Expression in Melanoma. Clinical Cancer Research, 2006, 12, 3297-3305.	3.2	39
116	Overall survival at 5 years of follow-up in a phase III trial comparing ipilimumab 10 mg/kg with 3 mg/kg in patients with advanced melanoma. , 2020, 8, e000391.		39
117	Vaccination of Stage IV patients with allogeneic IL-4- or IL-2-gene-transduced melanoma cells generates functional antibodies against vaccinating and autologous melanoma cells. Cancer Immunology, Immunotherapy, 2002, 51, 9-14.	2.0	38
118	Anti-CTLA-4 Antibody Adjuvant Therapy in Melanoma. Seminars in Oncology, 2010, 37, 455-459.	0.8	37
119	Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial. Lancet Oncology, The, 2021, 22, 655-664.	5.1	37
120	Circulating CD4+ T Cells That Produce IL4 or IL17 When Stimulated by Melan-A but Not by NY-ESO-1 Have Negative Impacts on Survival of Patients with Stage IV Melanoma. Clinical Cancer Research, 2014, 20, 4390-4399.	3.2	36
121	Primary Analysis and 4-Year Follow-Up of the Phase III NIBIT-M2 Trial in Melanoma Patients With Brain Metastases. Clinical Cancer Research, 2021, 27, 4737-4745.	3.2	35
122	Brain Metastasis in Melanoma: Clinical Activity of CTLA-4 Antibody Therapy. Seminars in Oncology, 2010, 37, 468-472.	0.8	33
123	Prevalence of hypophysitis in a cohort of patients with metastatic melanoma and prostate cancer treated with ipilimumab. Endocrine, 2017, 58, 535-541.	1.1	33
124	Epigenetics Meets Immune Checkpoints. Seminars in Oncology, 2015, 42, 506-513.	0.8	32
125	Genomic Features of Exceptional Response in Vemurafenib \pm Cobimetinib-treated Patients with <i>BRAF</i> ^{V600} -mutated Metastatic Melanoma. Clinical Cancer Research, 2019, 25, 3239-3246.	3.2	32
126	Expression and Functional Role of CD54/Intercellular Adhesion Molecule-1 (ICAM-1) on Human Blood Cells. Leukemia and Lymphoma, 1992, 8, 23-33.	0.6	31

#	ARTICLE	IF	CITATIONS
127	Effects of cyclophosphamide and IL-2 on regulatory CD4+ T cell frequency and function in melanoma patients vaccinated with HLA-class I peptides: impact on the antigen-specific T cell response. <i>Cancer Immunology, Immunotherapy</i> , 2013, 62, 897-908.	2.0	31
128	Heterogeneous distribution of BRAF/NRAS mutations among Italian patients with advanced melanoma. <i>Journal of Translational Medicine</i> , 2013, 11, 202.	1.8	31
129	NK and T cell subsets in malignant mesothelioma patients: Baseline pattern and changes in the context of anti-CTLA4 therapy. <i>International Journal of Cancer</i> , 2019, 145, 2238-2248.	2.3	31
130	Immune Checkpoint Inhibitors for Cancer Therapy in the COVID-19 Era. <i>Clinical Cancer Research</i> , 2020, 26, 4201-4205.	3.2	30
131	Tremelimumab plus durvalumab retreatment and 4-year outcomes in patients with mesothelioma: a follow-up of the open label, non-randomised, phase 2 NIBIT-MESO-1 study. <i>Lancet Respiratory Medicine</i> , 2021, 9, 969-976.	5.2	29
132	Differential modulation by tumor necrosis factor and immune interferon of HLA class-II antigens expressed by melanoma cells. <i>International Journal of Cancer</i> , 1989, 44, 554-559.	2.3	28
133	Update on the role of ipilimumab in melanoma and first data on new combination therapies. <i>Current Opinion in Oncology</i> , 2013, 25, 166-172.	1.1	27
134	Safety and efficacy of nivolumab in challenging subgroups with advanced melanoma who progressed on or after ipilimumab treatment: A single-arm, open-label, phase II study (CheckMate 172). <i>European Journal of Cancer</i> , 2019, 121, 144-153.	1.3	27
135	Overexpression of protectin (CD59) down-modulates the susceptibility of human melanoma cells to homologous complement. <i>Journal of Cellular Physiology</i> , 2000, 185, 317-323.	2.0	26
136	The cost of unresectable stage III or stage IV melanoma in Italy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2012, 31, 91.	3.5	25
137	The Ipilimumab Lesson in Melanoma: Achieving Long-Term Survival. <i>Seminars in Oncology</i> , 2015, 42, 387-401.	0.8	24
138	Methylation-regulated expression of cancer testis antigens in primary effusion lymphoma: Immunotherapeutic implications. <i>Journal of Cellular Physiology</i> , 2005, 202, 474-477.	2.0	23
139	Clinical experience with ipilimumab 10 mg/kg in patients with melanoma treated at Italian centres as part of a European expanded access programme. <i>Journal of Experimental and Clinical Cancer Research</i> , 2013, 32, 82.	3.5	23
140	Pregnancy and Malignant Neoplasms of the Head and Neck. <i>Annals of Otology, Rhinology and Laryngology</i> , 1998, 107, 991-998.	0.6	22
141	5-AZA-2-Deoxycytidine in Cancer Immunotherapy: A Mouse to Man Story. <i>Cancer Research</i> , 2007, 67, 2900-2900.	0.4	21
142	Immunological markers and clinical outcome of advanced melanoma patients receiving ipilimumab plus fotemustine in the NIBIT-M1 study. <i>OncImmunology</i> , 2016, 5, e1071007.	2.1	21
143	Neoadjuvant immunotherapy is reshaping cancer management across multiple tumour types: The future is now!. <i>European Journal of Cancer</i> , 2021, 152, 155-164.	1.3	21
144	COVID and Lung Cancer. <i>Current Oncology Reports</i> , 2021, 23, 134.	1.8	21

#	ARTICLE	IF	CITATIONS
145	CD40 Expression by Human Melanocytic Lesions and Melanoma Cell Lines and Direct CD40 Targeting With the Therapeutic Anti-CD40 Antibody CP-870,893. <i>Journal of Immunotherapy</i> , 2010, 33, 810-816.	1.2	20
146	Clinical and immunologic responses in melanoma patients vaccinated with MAGE-3 genetically modified lymphocytes. <i>International Journal of Cancer</i> , 2013, 132, 2557-2566.	2.3	20
147	Immunomodulatory Properties of DNA Hypomethylating Agents: Selecting the Optimal Epigenetic Partner for Cancer Immunotherapy. <i>Frontiers in Pharmacology</i> , 2018, 9, 1443.	1.6	20
148	SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: Clinical course and outcome. <i>European Journal of Cancer</i> , 2020, 133, 1-3.	1.3	20
149	Differential levels of soluble intercellular adhesion molecule-1 (sICAM-1) in early breast cancer and benign breast lesions. <i>Breast Cancer Research and Treatment</i> , 1999, 58, 19-23.	1.1	19
150	The overlooked ?nonclassical? functions of major histocompatibility complex (MHC) class II antigens in immune and nonimmune cells. <i>Journal of Cellular Physiology</i> , 1999, 179, 251-256.	2.0	19
151	Epigenetically regulated clonal heritability of CTA expression profiles in human melanoma. <i>Journal of Cellular Physiology</i> , 2010, 223, 352-358.	2.0	19
152	A randomized, open-label clinical trial of tasisulam sodium versus paclitaxel as second-line treatment in patients with metastatic melanoma. <i>Cancer</i> , 2014, 120, 2016-2024.	2.0	19
153	Health-related quality of life impact of cobimetinib in combination with vemurafenib in patients with advanced or metastatic BRAFV600 mutation-positive melanoma. <i>British Journal of Cancer</i> , 2018, 118, 777-784.	2.9	19
154	Circulating Levels of PD-L1 in Mesothelioma Patients from the NIBIT-MESO-1 Study: Correlation with Survival. <i>Cancers</i> , 2020, 12, 361.	1.7	19
155	Epigenetics of melanoma: implications for immune-based therapies. <i>Immunotherapy</i> , 2013, 5, 1103-1116.	1.0	18
156	CTLA4 blockade in mesothelioma: finally a competing strategy over cytotoxic/target therapy?. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 105-112.	2.0	18
157	Melanoma-Associated Hypopigmentation: Where Are the Antibodies?. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1996, 19, 613-618.	0.6	18
158	Epigenetic Immunomodulation of Hematopoietic Malignancies. <i>Seminars in Oncology</i> , 2005, 32, 503-510.	0.8	17
159	Expression and regulation of B7-3 immunoregulatory receptor, in human mesothelial and mesothelioma cells: Immunotherapeutic implications. <i>Journal of Cellular Physiology</i> , 2011, 226, 2595-2600.	2.0	17
160	Immune checkpoint blockade in malignant mesothelioma. <i>Oncolmmunology</i> , 2014, 3, e27482.	2.1	17
161	Thymosin β 1 in melanoma: from the clinical trial setting to the daily practice and beyond. <i>Annals of the New York Academy of Sciences</i> , 2012, 1270, 8-12.	1.8	14
162	Integrating Immune Checkpoint Blockade with Anti-Neo/Mutated Antigens Reactivity to Increase the Clinical Outcome of Immunotherapy. <i>Vaccines</i> , 2015, 3, 420-428.	2.1	14

#	ARTICLE	IF	CITATIONS
163	Ipilimumab versus placebo after complete resection of stage III melanoma: Initial efficacy and safety results from the EORTC 18071 phase III trial.. <i>Journal of Clinical Oncology</i> , 2014, 32, LBA9008-LBA9008.	0.8	14
164	Loss of Spry1 reduces growth of BRAFV600-mutant cutaneous melanoma and improves response to targeted therapy. <i>Cell Death and Disease</i> , 2020, 11, 392.	2.7	14
165	Long-term follow up of metastatic melanoma patients treated with Thymosin alpha-1: investigating immune checkpoints synergy. <i>Expert Opinion on Biological Therapy</i> , 2018, 18, 77-83.	1.4	13
166	Permanent diabetes insipidus in a patient with mesothelioma treated with immunotherapy. <i>Archives of Endocrinology and Metabolism</i> , 2020, 64, 483-486.	0.3	13
167	HLA and prognostic factors in primary breast cancer. <i>International Journal of Cancer</i> , 1985, 35, 581-585.	2.3	12
168	Is it the primetime for endoglin (CD105) in the clinical setting?. <i>Cardiovascular Research</i> , 2006, 69, 781-783.	1.8	12
169	Nivolumab improved survival vs dacarbazine in patients with untreated advanced melanoma. <i>Journal of Translational Medicine</i> , 2015, 13, .	1.8	12
170	Melanoma and immunotherapy bridge 2015. <i>Journal of Translational Medicine</i> , 2016, 14, 65.	1.8	12
171	Long-term survival in patients with metastatic melanoma who received ipilimumab in four phase II trials.. <i>Journal of Clinical Oncology</i> , 2013, 31, 9053-9053.	0.8	12
172	Back to simplicity: a four-marker blood cell score to quantify prognostically relevant myeloid cells in melanoma patients. , 2021, 9, e001167.		11
173	The pleiotropic roles of circular and long noncoding RNAs in cutaneous melanoma. <i>Molecular Oncology</i> , 2022, 16, 565-593.	2.1	11
174	Unbalanced expression of HLA-A and -B antigens: A specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN-?. <i>International Journal of Cancer</i> , 2001, 91, 500-507.	2.3	10
175	Expanded access programmes: patient interests versus clinical trial integrity. <i>Lancet Oncology</i> , The, 2015, 16, 15-17.	5.1	10
176	coBRIM: a phase 3, double-blind, placebo-controlled study of vemurafenib versus vemurafenib + cobimetinib in previously untreated BRAFV600 mutationâ€“positive patients with unresectable locally advanced or metastatic melanoma (NCT01689519). <i>Journal of Translational Medicine</i> , 2015, 13, O4.	1.8	10
177	Modulation by cytokines of HLA antigens, intercellular adhesion molecule 1 and high molecular weight melanoma associated antigen expression and of immune lysis of clones derived from the melanoma cell line MeM 50-10. <i>Cancer Immunology, Immunotherapy</i> , 1989, 30, 34-42.	2.0	8
178	In vitro analysis of the melanoma/endothelium interaction increasing the release of soluble intercellular adhesion molecule 1 by endothelial cells. <i>Cancer Immunology, Immunotherapy</i> , 1999, 48, 132-138.	2.0	8
179	Immune Checkpoint Blockade in Malignant Mesothelioma. <i>Seminars in Oncology</i> , 2015, 42, 418-422.	0.8	8
180	Immunotherapy targeting immune check-point(s) in brain metastases. <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 33-38.	3.2	8

#	ARTICLE	IF	CITATIONS
181	Immune checkpoint therapy of mesothelioma: Pre-clinical bases and clinical evidences. Cytokine and Growth Factor Reviews, 2017, 36, 25-31.	3.2	8
182	New horizons from immunotherapy in malignant pleural mesothelioma. Journal of Thoracic Disease, 2018, 10, S322-S332.	0.6	8
183	Recombinant transmembrane CD59 (CD59-TM) confers complement resistance to GPI-anchored protein defective melanoma cells*. Journal of Cellular Physiology, 2002, 190, 200-206.	2.0	7
184	Targeting of HLA-DR molecules transduces agonistic functional signals in cutaneous melanoma. Journal of Cellular Physiology, 2004, 200, 272-276.	2.0	7
185	Severe acute respiratory syndrome coronavirus 2 vaccination and cancer therapy: A successful but mindful mix. European Journal of Cancer, 2021, 156, 119-121.	1.3	7
186	First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers. Cancer Chemotherapy and Pharmacology, 2022, 89, 499-514.	1.1	7
187	Bioimmunotherapeutic targets on angiogenetic blood vessels in solid malignancies. Frontiers in Bioscience - Landmark, 2001, 6, d776.	3.0	6
188	Epigenetic Markers of Prognosis in Melanoma. Methods in Molecular Biology, 2014, 1102, 481-499.	0.4	6
189	Vemurafenib in BRAFV600 mutated metastatic melanoma: a subanalysis of the Italian population of a global safety study. Future Oncology, 2015, 11, 1355-1362.	1.1	6
190	Abstract CT039: INDUCE-1: a phase I open-label study of GSK3359609, an ICOS agonist antibody, administered alone and in combination with pembrolizumab in patients with selected, advanced solid tumors. Cancer Research, 2017, 77, CT039-CT039.	0.4	6
191	A phase 2 single-arm study with tremelimumab at an optimized dosing schedule in second-line mesothelioma patients.. Journal of Clinical Oncology, 2014, 32, 7531-7531.	0.8	6
192	Cancer testis antigens and melanoma stem cells: new promises for therapeutic intervention. Cancer Immunology, Immunotherapy, 2010, 59, 487-488.	2.0	5
193	A randomized, phase III study of fotemustine versus the combination of fotemustine and ipilimumab or the combination of ipilimumab and nivolumab in patients with metastatic melanoma with brain metastasis: the NIBIT-M2 trial.. Journal of Clinical Oncology, 2015, 33, TPS9090-TPS9090.	0.8	5
194	Nivolumab plus ipilimumab in melanoma brain metastases. Lancet Oncology, The, 2022, 23, e53.	5.1	5
195	Signaling by HLA class II antigens on B cells. Trends in Immunology, 1995, 16, 548.	7.5	4
196	Optimizing complement-activating antibody-based cancer immunotherapy: a feasible strategy?. Journal of Translational Medicine, 2004, 2, 21.	1.8	4
197	Diagnostic and Therapeutic Approaches in Italian Hospitals: Adjuvant and Metastatic Therapy in Melanoma. Dermatology, 2013, 226, 22-27.	0.9	4
198	Immune checkpoint blockade therapy of mesothelioma: a clinical and radiological challenge. Cancer Immunology, Immunotherapy, 2018, 67, 1317-1324.	2.0	4

#	ARTICLE	IF	CITATIONS
199	Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.. Journal of Clinical Oncology, 2021, 39, 2565-2565.	0.8	4
200	Abstract CT270: A randomized, multi-center, phase II study of nivolumab combined with ipilimumab and guadecitabine or nivolumab combined with ipilimumab in melanoma and NSCLC patients resistant to anti-PD-1/-PD-L1: The NIBIT-ML1 Study. , 2020, , .		4
201	Ipilimumab (Ipi) retreatment at 10 mg/kg in patients with metastatic melanoma previously treated in phase II trials.. Journal of Clinical Oncology, 2013, 31, 9059-9059.	0.8	4
202	BRIM8: A phase III, randomized, double-blind, placebo-controlled study of vemurafenib adjuvant therapy in patients with surgically resected, cutaneous BRAF-mutant melanoma at high risk for recurrence (NCT01667419).. Journal of Clinical Oncology, 2014, 32, TPS9118-TPS9118.	0.8	4
203	KEYNOTE-022: Pembrolizumab with trametinib in patients with BRAF wild-type melanoma or advanced solid tumours irrespective of BRAF mutation. European Journal of Cancer, 2022, 160, 1-11.	1.3	4
204	The Association Between Congenital Adrenal Hyperplasia and HLA in Southern Italy. Annals of the New York Academy of Sciences, 1985, 458, 46-51.	1.8	3
205	European approach to antibody-based immunotherapy of melanoma. Seminars in Oncology, 2002, 29, 471-478.	0.8	3
206	The Italian Network for Tumor Biotherapy (NIBIT). Sharing Visions, Goals and Efforts at European Level. Tumori, 2008, 94, 179-181.	0.6	3
207	Longitudinal Study of Recurrent Metastatic Melanoma Cell Lines Underscores the Individuality of Cancer Biology. Journal of Investigative Dermatology, 2014, 134, 1389-1396.	0.3	3
208	Biomarkers for immune checkpoint inhibitors â€œ Authors' reply. Lancet Oncology, The, 2014, 15, e1-e2.	5.1	3
209	Fourteenth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT) on Cancer Bio-Immunotherapy, Siena, Italy, October 13â€“15, 2016. Cancer Immunology, Immunotherapy, 2018, 67, 1023-1030.	2.0	3
210	A vision of immuno-oncology: the Siena think tank of the Italian network for tumor biotherapy (NIBIT) foundation. Journal of Experimental and Clinical Cancer Research, 2021, 40, 240.	3.5	3
211	Epigenetic Immune Remodeling of Mesothelioma Cells: A New Strategy to Improve the Efficacy of Immunotherapy. Epigenomes, 2021, 5, 27.	0.8	3
212	Health-related quality of life in patients treated with pembrolizumab for microsatellite instabilityâ€œhigh/mismatch repairâ€œdeficient advanced solid tumours: Results from the KEYNOTE-158 study. European Journal of Cancer, 2022, 169, 188-197.	1.3	3
213	SARS-CoV-2 infection in cancer patients on active therapy after the booster dose of mRNA vaccines. European Journal of Cancer, 2022, 171, 143-149.	1.3	3
214	Introduction to Immunologic Checkpoints for Cancer Treatment: From Scientific Rationale to Clinical Application. Seminars in Oncology, 2010, 37, 429.	0.8	2
215	ICOS Expression as Immunologic Marker in Immune Activating Monoclonal Antibodies. Methods in Molecular Biology, 2016, 1393, 133-139.	0.4	2
216	Immunotherapy Bridge 2017 and Melanoma Bridge 2017: meeting abstracts. Journal of Translational Medicine, 2018, 16, .	1.8	2

#	ARTICLE	IF	CITATIONS
217	The future of mesothelioma treatment: time to shift gear. <i>Lancet Respiratory Medicine</i> , 2019, 7, 554-555.	5.2	2
218	The Italian Network for Tumor Biotherapy (NIBIT): past, present and future goals. <i>Reviews in Health Care</i> , 2014, 5, 3-6.	0.1	2
219	Abstract CT557: Phase 1/2 study of quavonlimab (Qmab) + pembrolizumab (pembro) in patients (pts) with advanced melanoma that progressed on a PD-1/PD-L1 inhibitor. <i>Cancer Research</i> , 2022, 82, CT557-CT557.	0.4	2
220	Epigenetically regulated tumor-associated antigens in melanoma. <i>Expert Review of Dermatology</i> , 2009, 4, 145-154.	0.3	1
221	Goals and objectives of the Italian Network for Tumor Biotherapy (NIBIT). <i>Cytokine and Growth Factor Reviews</i> , 2017, 36, 1-3.	3.2	1
222	The Italian Network for Tumor Bio-Immunotherapy (NIBIT) Foundation: ongoing and prospective activities in immuno-oncology. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 143-150.	2.0	1
223	Serafino Zappacosta: An Enlightened Mentor and Educator. <i>Frontiers in Immunology</i> , 2020, 11, 217.	2.2	1
224	Unbalanced expression of HLA-A and -B antigens: A specific feature of cutaneous melanoma and other non-hemopoietic malignancies reverted by IFN- γ . <i>International Journal of Cancer</i> , 2001, 91, 500-507.	2.3	1
225	Introduction: Melanoma: American and European perspectives on diagnosis and treatment. <i>Seminars in Oncology</i> , 2002, 29, 306-307.	0.8	0
226	Biomolecular strategies for therapeutic intervention in cancer. <i>Oncogene</i> , 2003, 22, 6469-6469.	2.6	0
227	Introduction: Cancer Epigenetics and Epigenetic Treatment of Cancer. <i>Seminars in Oncology</i> , 2005, 32, 435-436.	0.8	0
228	“Cancer Bio-Immunotherapy in Siena” Eleventh Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 17-19, 2013. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 131-135.	2.0	0
229	Immunologic Checkpoints for Cancer Treatment: A Continuing Success. <i>Seminars in Oncology</i> , 2015, 42, 362.	0.8	0
230	“Cancer Bio-Immunotherapy in Siena” Twelfth Meeting of the Network Italiano per la Bioterapia dei Tumori (NIBIT), Siena, Italy, October 9-11, 2014. <i>Cancer Immunology, Immunotherapy</i> , 2016, 65, 119-126.	2.0	0
231	Perspectives of Immunotherapy in Advanced Melanoma: Combinations and Sequencing. , 2021, , 281-310.		0
232	Endoglin (CD105): A Strong Candidate for Immunologic Targeting of Tumor Neovasculature in Human Malignancies. , 2008, , 395-410.		0